This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Colorectal cancer; inflammatory bowel disease (IBD)	Solute carrier family 3 member 2 (SLC3A2; CD98)	Studies in mice suggest that inhibiting CD98 could help prevent or treat IBD and colitis-associated cancer. In mice, low Cd98 expression in intestinal epithelial cells decreased susceptibility to chemical-induced colitis and colitis-associated cancer compared with that in wild-type controls. Next steps include using nanoparticle-based systems to deliver CD98 small interfering RNAs specifically to sites of intestinal inflammation.	Unpatented; unavailable for licensing	<p>Nguyen, H.T.T. <i>et al. J. Clin. Invest.</i>; published online April 1, 2011; doi:10.1172/JCI44631</p> <p>Contact: Hang Thi Thu Nguyen, Emory University, Atlanta, Ga. e-mail: hnguye9@emory.edu</p>
<p><i>SciBX</i> 4(15); doi:10.1038/scibx.2011.435 Published online April 14, 2011</p>				